Monitor the satisfaction of closing conditions, particularly the independent valuation opinion and auditor concurrence on equity classification, which are critical for the Nasdaq compliance narrative. The key catalyst is whether the definitive channel agreements with AHA and Cleveland Clinic Weston are executed and whether the pseudohypoxia test achieves clinical validation — without those, the $12 million stated value is purely accounting-driven and the dilution overhang remains substantial.
Price Chart
Executive Summary
Vivos Therapeutics entered into a definitive agreement to acquire an 11% fully diluted equity stake in SOD Sciences and a 50% undivided co-ownership interest in SOD's proprietary pseudohypoxia early-warning test, in exchange for issuing 12,000 shares of Series C Convertible Preferred Stock with an aggregate stated value of $12 million. The transaction is designed to boost Vivos' stockholders' equity above Nasdaq's $2.5 million minimum requirement (pro forma equity of ~$8 million) and open potential commercial channels through American Health Associates and Cleveland Clinic Weston. No cash changes hands, but the preferred stock is convertible into up to 80 million common shares at $0.15/share, subject to a 19.99% exchange cap and a 4.99% beneficial ownership limitation, creating massive potential dilution.
Key Financial Metrics
Key Facts
- Vivos issues 12,000 shares of Series C Convertible Preferred Stock with $12 million aggregate stated value to SOD Sciences in exchange for an 11% fully diluted equity stake in SOD and a 50% undivided co-ownership interest in the pseudohypoxia early-warning test IP.
- Conversion price fixed at $0.15/share; at that price, the preferred is convertible into up to 80 million common shares, subject to a 19.99% exchange cap (pending stockholder approval) and a 4.99% beneficial ownership limitation.
- No cash consideration is payable; the transaction is expected to increase Vivos' stockholders' equity to approximately $8 million on a pro forma basis, exceeding Nasdaq's $2.5 million minimum requirement by $5.5 million.
- Closing is subject to conditions including an independent valuation opinion, auditor concurrence on equity classification, consent from Series B holder Streeterville Capital, and Nasdaq notification.
- Post-closing, Vivos will retain 80% of contribution margin on sales of its products through AHA and Cleveland Clinic channels, and share 50/50 on sales of the jointly owned test.
- SOD has a marketing term sheet with American Health Associates (covering ~3,000 facilities across 25 states) and a Memorandum of Understanding with Cleveland Clinic Weston for an IRB-approved study and commercial program to transition over 2,000 CPAP patients to Vivos devices.
- The agreement includes an anti-dilution covenant preventing SOD from issuing additional equity through April 16, 2027 without Vivos' consent, with a pro rata participation right for Vivos to maintain its 11% stake.
- Vivos intends to seek stockholder approval at its next annual meeting to allow conversion above the 19.99% exchange cap.
Financial Impact
Pro forma stockholders' equity of approximately $8 million, reflecting $12 million stated value of Series C Preferred allocated to investment in subsidiary. No cash consideration. Potential massive dilution: up to 80 million shares at $0.15 conversion price, capped at 19.99% of pre-signing outstanding shares pending stockholder approval.
Risk Factors
- Massive potential dilution: up to 80 million shares at $0.15 conversion price, with the 19.99% exchange cap only a temporary constraint pending stockholder approval.
- Closing conditions may not be satisfied (valuation opinion, auditor concurrence, Streeterville consent, Nasdaq notification), and the agreement terminates if not closed by October 15, 2026.
- The AHA marketing term sheet and Cleveland Clinic MOU are non-binding; definitive agreements may not be executed on favorable terms or at all.
- The pseudohypoxia test requires clinical validation and regulatory clearance; Vivos' existing FDA clearances do not extend to this test.
- Vivos was already non-compliant with Nasdaq's minimum stockholders' equity requirement; even with the pro forma boost, maintaining compliance is not guaranteed.
- Management intends to seek additional capital after the Nasdaq compliance milestone, which could further dilute existing shareholders.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-047158 |
| Exhibit: ex99-1.htm | 0001493152-26-047158 |
| Document: form8-k.htm | 0001493152-26-047158 |
| Document: 0001493152-26-047158-index-headers.html | 0001493152-26-047158 |
| Document: 0001493152-26-047158-index.html | 0001493152-26-047158 |
| Document: 0001493152-26-047158.txt | 0001493152-26-047158 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1313 (−2.52%) |
Oct 19, 2026 7d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1313 (−6.88%) |
Oct 19, 2026 7d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1313 (−6.61%) |
Oct 15, 2026 11d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1313 (−8.05%) |
Oct 15, 2026 11d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1313 (−8.05%) |
Sep 30, 2026 25d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1313 (+11.88%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1313 (−41.62%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1313 (−52.57%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1313 (+56.41%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1313 (−61.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers